Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide

Sanofi-Aventis and Zealand Pharma have gained some ammunition as they prepare to enter the competitive GLP-1 agonist market, with data from a head-to-head study showing their lixisenatide to be non-inferior to Lilly/Amylin's Byetta (exenatide).